Angiogenesis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vascular Endothelial Growth Factor
New vascular endothelial growth factor study findings have been reported by scientists at National Institutes of Health
June 19th, 2009
"VEGF-B, a homolog of VEGF discovered a long time ago, has not been considered an important target in antiangiogenic therapy. Instead, it has received little attention from the field," scientists in the United States report. "In this study, using different animal models and multiple types of vascular cells, we revealed that although VEGF-B is dispensable for blood vessel growth, it is critical for their survival. Importantly, the survival effect of VEGF-B is not only on vascular endothelial cells, but also on pericytes, smooth muscle cells, and vascular stem/progenitor cells. In vivo, VEGF-B targeting inhibited both choroidal and retinal neovascularization....
Source: Angiogenesis Weekly (2009-06-19)
|
